PT-141
Bremelanotide (Melanocortin Receptor Agonist)
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its effects on sexual function through central nervous system pathways rather than vascular mechanisms. Unlike PDE5 inhibitors that act peripherally, PT-141 works through melanocortin-4 receptors in the brain. It is one of the most studied peptides in sexual health research, with extensive published clinical data.
Aliases: Bremelanotide, Vyleesi
- Research score
- 9/10
Mechanism
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It activates MC3R and MC4R receptors in the hypothalamus, triggering downstream neural signaling cascades that modulate sexual arousal and desire through central nervous system pathways rather than peripheral vasodilation. The MC4R activation increases dopaminergic and oxytocinergic signaling in brain regions associated with sexual motivation. Notably, it works independently of nitric oxide/PDE5 pathways (unlike sildenafil/tadalafil).
Evidence note
Established — FDA-approved as Vyleesi for female HSDD. Multiple Phase 3 trials. Well-characterized mechanism. Clinical use in both genders supported by data.
Studies
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Dose-dependent increase in erectile activity in healthy men and ED patients. Works through central melanocortin receptors, not peripheral vasodilation.
Open source · PMID 12851303RECONNECT Phase 3 trials — Bremelanotide for HSDD in premenopausal women
Statistically significant improvement in sexual desire and reduction in distress scores in women with HSDD. Basis for FDA approval of Vyleesi in 2019.
PT-141 in male erectile dysfunction: efficacy in PDE5 inhibitor non-responders
Effective in men who had failed PDE5 inhibitors (Viagra/Cialis). Works through entirely different CNS pathway — melanocortin vs nitric oxide/PDE5.
FAQ
How is PT-141 different from Viagra or Cialis?
PT-141 works through the central nervous system (melanocortin receptors in the brain) to increase sexual desire and arousal. Viagra and Cialis work peripherally by increasing blood flow through PDE5 inhibition. PT-141 affects desire, not just mechanics — which is why it works in some people who don't respond to PDE5 inhibitors. It's also one of the few compounds studied for female sexual dysfunction.
How often can PT-141 be used?
PT-141 is used as-needed, not on a daily cycle like most peptides. FDA labeling for Vyleesi recommends no more than 1 dose per 24 hours and no more than 8 doses per month. Most research protocols use 0.5-2mg SC administered 1-4 hours before anticipated activity. Start at the low end (0.5mg) to assess nausea tolerance before increasing.
Does PT-141 cause nausea?
Nausea is the most commonly reported side effect — approximately 40% of women in clinical trials experienced it. In men, rates are lower but still notable. The nausea is typically transient (30-60 minutes) and dose-dependent. Community tip: start at 0.5mg and increase gradually. Taking it on an empty stomach and staying hydrated may help.
For research and educational use only. This content is not medical advice.